The effectiveness of moxifloxacin in the treatment of community-acquired pneumonia

The article presents the results of domestic and international studies of the use of the fourth-generation fluoroquinolone moxifloxacin in the treatment of commu-nity-acquired pneumonia and pneumonia caused by SARS-CoV-2. Analysis of the clinical use of moxifloxacin in the treatment of complications of the respiratory tract infec-tions indicates its high efficiency and bioavailability, a low risk of resistance, which makes it possible to recommend it for widespread use in the work of a practicing doctor. Ge-neric drug Maxicin (Yuria-Pharm), available as a 20 mg/ml concentrate in a 20 ml vial, can significantly reduce the cost of treatment and optimize infusion therapy by choosing both volume and solvent.

Streptococci in Children's Respiratory Infections: Diagnosis and Treatment

Many pediatricians include nose and throat cultures in their management of children with minor respiratory-tract infec tions. They believe that the best safeguard against rheu matic fever and other complications of hemolytic strepto coccic infections is to identify that organism when present, and then give some antibiotic, usually penicillin, liberally. Thorough attention to the observations in this careful report will help to make our judgments more sound and helpful.